Funding Wizard

The FY23 ARP Idea Development Award supports the development of innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with ASD. Applications are strongly encouraged to address one of the FY23 ARP Idea Development Award Areas of Interest or provide justification that the proposed research addresses a critical problem, question, or need in ASD. This award mechanism is designed to support innovative ideas with the potential to yield impactful data and new avenues of investigation.

The Clinical Translational Research Award intends to support correlative studies that are associated with a clinical trial (past, ongoing, or future), in order to correlate various factors (genetic, biochemical, environmental and others) with initiation, progression, metastasis, recurrence, prognosis, diagnosis or effect of intervention on ovarian cancer outcomes. The translational research should address high-impact or unmet needs in ovarian cancer. Although not all-inclusive, research proposed under this mechanism may entail initiation of a deeper molecular analysis of clinical samples, biomarker validation, or continuing clinical follow-up of patients currently/previously enrolled in an open/ongoing or completed clinical trial. The proposed research may be hypothesis testing or may be designed to generate clinically annotated and molecularly characterized experimental platforms (e.g., tissue arrays, patient-derived models).

The intent of the FY23 TCA is to support research that focuses on the realities of everyday living for the individual with AD/ADRD, their care partner/caregiver, and/or both, as well as the reaching impact on families and communities. For the purposes of this funding mechanism, “care” does not include medical care (such as medical interventions administered by a physician), as the care landscape extends beyond that of medical interventions to be inclusive of research into integration, education, and support.Key elements of this mechanism are:Person-centered research: All applications to the FY23 PRARP TCA should be person-centered. This mechanism is intended to provide answers and solutions in critical areas to improve quality of life, reduce burden and stress, and increase support for care partners. The research should have near-immediate impact on the intended beneficiaries. To facilitate success, the TCA requires community collaboration for all projects.Focus on outcomes: The intent of the TCA is to advance knowledge and capacity in the AD/ADRD care field. As such, applicants should clearly articulate outcomes, clearly demonstrate a pathway of feasibility and identify realistic approaches to scaling and community level implementation for widespread use. Additionally, applications should plan for and describe how the research will be manualized and fed back into the to the research, lived experience, and care communities. A milestone meeting will be requiredProjects supported by this mechanism must represent a non-incremental advance in the care field. Preliminary data are required. For this mechanism, studies utilizing animal models are not allowed.

Attention San Joaquin Valley residents! The Valley Air District provides several great options to significantly reduce or even eliminate the pollution that comes from using your car.

The purpose of the Pesticide Environmental Stewardship Program Grant Initiative is to encourage smart, sensible and sustainable pest control in agriculture. The initiative, which is an extension of the Pesticide Environmental Stewardship Program (PESP), will enable grantees to implement sustainable pest management practices that align with the Agency’s strategic goal of providing a cleaner and healthier environment for all Americans and contribute to reductions in greenhouse gas emissions. Proposed projects should address implementation of environmentally sound pest management practices, approaches, training, and innovations that reduce the risks associated with pesticide use in agricultural settings and, where feasible, lead to corresponding reductions in greenhouse gas emissions that contribute to climate change. These projects will reduce unnecessary exposures to pests and pesticides through the adoption of integrated pest management practices and strengthen our shared goals of sustainable pest management and its intersection with climate change.

Proposers must retrieve the instructions document (zip file) associated with the application package for this opportunity as there is at least one required form that must be attached to the submitted proposal package. The National Aeronautics and Space Administration (NASA) Science Mission Directorate (SMD) released its annual omnibus Research Announcement (NRA), Research Opportunities in Space and Earth Sciences (ROSES) – 2021 (OMB Approval Number 2700-0092, CFDA Number 43.001) on February 12, 2021. In this case "omnibus" means that this NRA has many individual program elements, each with its own due dates and topics. All together these cover the wide range of basic and applied supporting research and technology in space and Earth sciences supported by SMD. Awards will be made as grants, cooperative agreements, contracts, and inter- or intra-agency transfers, depending on the nature of the work proposed, the proposing organization, and/or program requirements. However, most extramural research awards deriving from ROSES will be grants, and many program elements of ROSES specifically exclude contracts, because contracts would not be appropriate for the nature of the work solicited. The typical period of performance for an award is three years, but some programs may allow up to five years and others specify shorter periods. In most cases, organizations of every type, Government and private, for profit and not-for-profit, domestic and foreign (with some caveats), may submit proposals without restriction on teaming arrangements. Tables listing the program elements and due dates, the full text of the ROSES-2021 solicitation, and the "Summary of Solicitation" as a stand-alone document, may all be found NSPIRES at http://solicitation.nasaprs.com/ROSES2021. This synopsis is associated with one of the individual program elements within ROSES, but this is a generic summary that is posted for all ROSES elements. For specific information on this particular program element download and read the PDF of the text of this program element by going to Tables 2 or 3 of this NRA at http://solicitation.nasaprs.com/ROSES2021table2 and http://solicitation.nasaprs.com/ROSES2021table3, respectively, click the title of the program element of interest, a hypertext link will take you to a page for that particular program element. On that page, on the right side under "Announcement Documents" the link on the bottom will be to the PDF of the text of the call for proposals. For example, if one were interested in The Lunar Data Analysis Program (NNH21ZDA001N-LDAP) one would follow the link to the NSPIRES page for that program element and then to read the text of the call one would click on “C.8 Lunar Data Analysis (.PDF)” to download the text of the call. If one wanted to set it into the context of the goals, objectives and know the default rules for all elements within Appendix C, the planetary science division, one might download and read “C.1 Planetary Science Research Program Overview (.PDF)” from that same page. While the letters and numbers are different for each element within ROSES (A.12, B.7, etc.) the basic configuration is always the same, e.g., the letter indicates the Science Division (A is Earth Science, B is Heliophysics etc.) and whatever the letter, #1 is always the overview. Frequently asked questions for ROSES are posted at http://science.nasa.gov/researchers/sara/faqs. Questions concerning general ROSES-2021 policies and procedures may be directed to Max Bernstein, Lead for Research, Science Mission Directorate, at sara@nasa.gov, but technical questions concerning specific program elements should be directed to the point(s) of contact for that particular element, who may be found either at the end of the individual program element in the summary table of key information or on the web list of topics and points of contact at: http://science.nasa.gov/researchers/sara/program-officers-list. Not all program elements are known at the time of the release of ROSES. To be informed of new program elements or amendments to this NRA, proposers may subscribe to: (1) The SMD mailing lists (by logging in at http://nspires.nasaprs.com and checking the appropriate boxes under "Account Management" and "Email Subscriptions"), (2) The ROSES-2021 RSS feed for amendments, clarifications, and corrections to at http://science.nasa.gov/researchers/sara/grant-solicitations/ROSES-2021, and (3) The ROSES-2021 due date Google calendars (one for each science division). Instructions are at https://science.nasa.gov/researchers/sara/library-and-useful-links (link from the words due date calendar).

The FY22 BMFRP IIRA will offer two funding levels with different intent:Funding Level 1 (FL1): To support studies that further develop ideas, expand upon key discoveries, and have the potential to make significant advances in research, patient care, and/or quality of life in the FY22 BMFRP IIRA Focus Areas. IIRA applications may involve basic, translational, and clinically oriented research, including studies in animal models, research with human anatomical substances, and research with human subjects, as well as correlative studies associated with an existing clinical trial; however, FL1 awards may not be used to support a clinical trial. Multidisciplinary collaborations are encouraged.Funding Level 2 (FL2): To support Investigational New Drug (IND)-enabling efforts. The BMFRP recognizes the scientific and financial challenges associated with advancing promising, potentially life-changing, therapeutic agents from the laboratory to clinical evaluation. Data related to lead compound characterization; formulation and stability; absorption, distribution, metabolism and excretion; dose/response; and toxicology are required before clinical trials can commence. The proposed studies under the FL2 IND-enabling efforts are expected to be empirical in nature, product-driven, and focused on the accumulation of data for a lead therapeutic candidate(s). At least one, and no more than three, lead therapeutic candidates must be named at the time of application submission to meet the intent of the FL2 mechanism. Library screening or drug optimization studies do not meet the intent of FL2. At the end of the period of performance, the cumulative data should be sufficient to submit an IND to the Food and Drug Administration (FDA). The intent of FL2 awards is to perform the necessary evaluation of promising therapies that will lead to clinical trials; however, clinical trials themselves are not supported by this mechanism. FL2 applications must address the FY22 BMFRP Focus Area “Find effective BMF treatments and cures”.The following are significant features of this award mechanism:• Impact: Proposed research projects should address a central critical issue or question in BMF disease research or clinical care. High-impact research, if successful, will significantly advance current methods and concepts for the prevention, detection, diagnosis, and/or treatment of BMF diseases.• Translational Potential: The translational potential of the project should be considered and described. Applications should address how the research will translate findings into prevention strategies and/or a cure for BMF diseases.• Preliminary Data: Observations that drive a research idea may be derived from laboratory discovery, population-based studies, a clinician’s first-hand knowledge of patients, or anecdotal data. Applications must include preliminary and/or published data that are relevant to the mission of the BMFRP and support the proposed research project. Any unpublished preliminary data provided should originate from the laboratory of the Principal Investigator (PI) or a member(s) of the research team.• Multidisciplinary Collaborations: Applicants are encouraged, but not required, to form multidisciplinary teams of investigators who bring specific skills that contribute to the successful completion of the project. This can include both intellectual input and research resources (e.g., supplies, reagents, equipment, personnel, services, tissue samples, access to patients or populations).• Correlative Studies: Applications to FL1 are encouraged to propose correlative studies of open/ongoing or completed clinical trials to better characterize treatment response and provide deeper insights that can be used to develop future clinical trial endpoints or support personalized medicine approaches.Partnering PI Option: The IIRA encourages applications that include meaningful and productive collaborations between investigators and includes an option for more than one PI. Electing to submit to the partnering PI option does not influence the total direct cost limit as outlined in Section II.D.5, Funding Restrictions. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development of the proposed research project, including the Project Narrative, Statement of Work (SOW), and other required components. If recommended for funding, each PI will be named to an individual award within the recipient organization. For individual submission requirements for the Initiating and Partnering PI, refer to Section II.D.2, Content and Form of the Application Submission.

The Community Assistance Program - State Support Services element (CAP-SSSE) program provides funding to States to provide technical assistance to communities in the National Flood Insurance Program (NFIP) and to evaluate community performance in implementing NFIP floodplain management activities. Designation, duties, and responsibilities of State Coordinating Agencies are found in 44 CFR 60.25. These regulations identify the states commitment to the minimum floodplain management criteria and to demonstrate the capability and responsibility to implement the program. In this way, CAP-SSSE helps to; ensure that the flood loss reduction goals of the NFIP are met, build state and community floodplain management expertise and capability, and leverage state knowledge and expertise in working with their communities.

The LRP Idea Award supports innovative, high-risk/high-reward research that could ultimately lead to a critical discovery or major advancement relevant to lupus. This award mechanism supports studies that have the potential to reveal entirely new avenues for investigation. The application must describe how the new idea will enhance the existing knowledge of lupus or develop a hypothesis(es) or an innovative and novel course of investigation. The Idea Award is not intended to support an incremental progression of an already established research project. Research completed through an Idea Award may generate sufficient preliminary data to enable the Principal Investigator (PI) to prepare an application for future research. Inclusion of preliminary data is not required.The following are important aspects of the Idea Award:• Innovation: Innovative research may introduce a new paradigm, look at existing problems from new perspectives, or exhibit other highly creative qualities. It is the responsibility of the PI to clearly and explicitly describe how the proposed research is innovative and will lead to novel avenues of investigation in lupus research.• Impact: The proposed research, if successful, should impact an area of paramount importance in lupus disease. Applications should clearly and explicitly describe the potential impact(s) of the proposed study for individuals living with lupus and to convey its level of significance. Research that represents an incremental advancement on previously published work is not considered impactful.• Research Strategy: The scientific rationale and experimental methodology should demonstrate critical understanding and in-depth analysis of lupus. Experimental strategies may be novel or may be based on strong rationale derived from a literature review.• Focus Areas: The proposed research must address at least one of the FY22 LRP Focus Areas.• Clinical trials are not allowed under this program announcement.The types of awards made under the program announcement will be assistance agreements. An assistance agreement is appropriate when the federal government transfers a “thing of value” to a “state, local government,” or “other recipient” to carry out a public purpose of support or by a law of the United States instead of acquiring property or service for the direct benefit and use of the U.S. government. An assistance agreement can take the form of a grant or cooperative agreement. The level of involvement on the part of the Department of Defense (DOD) during project performance is the key factor in determining whether to award a grant or cooperative agreement. If “no substantial involvement” on the part of the funding agency is anticipated, a grant award will be made (31 USC 6304). Conversely, if substantial involvement on the part of the funding agency is anticipated, a cooperative agreement will be made (31 USC 6305), and the award will identify the specific substantial involvement. Substantial involvement may include, but is not limited to, collaboration, participation, or intervention in the research to be performed under the award. The award type, along with the start date, will be determined during the negotiation process.The anticipated total costs budgeted for the entire period of performance for an FY22 Idea Award will not exceed $300,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards will be made no later than September 30, 2023. For additional information refer to Section II.F.1, Federal Award Notices.The CDMRP expects to allot approximately $1.2M to fund approximately four Idea Award applications. Funding of applications received is contingent upon the availability of federal funds for this program as well as the number of applications received, the quality and merit of the applications as evaluated by scientific and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY22 funding opportunity will be funded with FY22funds, which will expire for use on September 30, 2023.

The intent of the FY22 CPMRP is to support studies that have the potential to make significant advances in the research, patient care and/or quality of life in the FY22 CPMRP IIRA Focus Areas. IIRA applications may involve basic, translational, and clinically oriented research, including studies in animal models, research with human anatomical substances, and research with human subjects, as well as correlative studies associated with an existing clinical trial; however, this award may not be used to conduct clinical trials. Multidisciplinary collaborations and innovative approaches are encouraged. Studies seeking to advance new and novel opioid-based therapeutic interventions do not meet the intent of the award mechanism and will not be selected for funding. Studies seeking to understand and reduce opioid utilization in chronic pain management within the context of current prescribing practices are acceptable.